Pfizer Inc. (PFE)
After hours:
| Previous Close | 48.58 |
| Open | 48.84 |
| Bid | 49.05 x 800 |
| Ask | 49.13 x 1400 |
| Day's Range | 48.73 - 49.44 |
| 52 Week Range | 40.94 - 61.71 |
| Volume | |
| Avg. Volume | 20,234,166 |
| Market Cap | 275.847B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 9.69 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.60 (3.25%) |
| Ex-Dividend Date | Jul 28, 2022 |
| 1y Target Est | N/A |
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, August 19, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical, at the Handelsbanken Life Science Innovation Day 2022 on Wednesday, August 24, 2022 at 4:30 p.m. CEST (10:30 a.m. EDT).
- Business Wire
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
- Business Wire
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
